龚邵新,赵强,曾庆彪,丁慧.ER、PR和C-erbB-2在乳腺浸润性导管癌中的表达及其相关性.[J].中南医学科学杂志.,2011,39(3):314-316.
ER、PR和C-erbB-2在乳腺浸润性导管癌中的表达及其相关性
Expression and Clinical Significance of ER、PR and C-erbB-2 in Breast Infiltrating Ductal Carcinoma
投稿时间:2010-12-31  
DOI:
中文关键词:  乳腺癌  ER  PR  C-erbB-2  免疫组化
英文关键词:breast cacer  ER  PR  C-erbB-2  immunohistochemistry
基金项目:
作者单位
龚邵新,赵强,曾庆彪,丁慧 南华大学第一附属医院 病理科湖南 衡阳 421001 
摘要点击次数: 682
全文下载次数: 641
中文摘要:
      目的探讨ER、PR和C-erbB-2在乳腺浸润性导管癌中的表达及其相关性。方法收集84例乳腺浸润性导管癌石蜡标本,应用免疫组化“二步法”检测ER、PR和C-erbB-2在上述病变中的表达。结果ER阳性57例,PR阳性42例,C-erbB-2阳性58例,ER、PR和C-erbB-2表达与乳腺癌患者年龄、肿瘤大小、淋巴结转移情况没有明显相关性。ER和PR的表达与C-erbB-2的表达没有明显相关性。ER、PR表达呈正相关。乳腺癌患者的年龄与淋巴结是否转移没有明显相关性。结论ER、PR和C-erbB-2的表达与临床各因素无明显相关性,联合检测ER、PR及C-erbB-2对临床上判断乳腺癌预后、指导治疗的意义不确定。
英文摘要:
      ObjectiveTo study the expression and clinical significance of ER,PR and C-erbB-2 in breast infiltrating ductal carcinoma.MethodsThe samples of 84 breast infiltrating ductal carcinoma were collected,then the expression of ER,PR and C-erbB-2 were detected with 2 step method.ResultsThe positive expression of ER,PR and C-erbB-2 were 57,42,58 respectively,which weren’t correlated with patient age,lump size and lymphatic metastasis.The expression of ER and PR had no correlation with the expression of C-erbB-2(P>0.05).The expression of Er was positively correlated with the expression of PR(P<0.05).ConclusionsThere were no obvious relations between the expression of ER,PR,C-erbB-2 and clinical factors.The expression of ER,PR and C-erbB-2 has an indefinite significance for predicting the prognosis of breast cancer paients.
查看全文  查看/发表评论  下载PDF阅读器
关闭
function PdfOpen(url){ var win="toolbar=no,location=no,directories=no,status=yes,menubar=yes,scrollbars=yes,resizable=yes"; window.open(url,"",win); } function openWin(url,w,h){ var win="toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=no,width=" + w + ",height=" + h; controlWindow=window.open(url,"",win); } &et=C84FD2BF879E0469FB45732ABC5FC4289420AADA2AD55F38650D8AB7C88CA423C78AEC6583B79E53FF0A3469131F9BA3FBF14F51CA7449B3BE16423DA7069E4AA55BF9035E63820B554B6CE6E95ADF734E113C738864C8893BE3B3E5ABC1B50CCF90FDDFD52669A7&pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=BB33F1C95224820A&jid=6A20DF2A798996E24F064D5ECF83A153&yid=9377ED8094509821&aid=DD26710B4E10EE67C11B9FB745308A57&vid=&iid=38B194292C032A66&sid=AA5FB09E1F81059E&eid=EC34D52BE81085CE&fileno=20110323&flag=1&is_more=0">